INS and fatty liver disease: Several animal models have demonstrated that the potent SPT inhibitor myriocin, frequently used to suppress de novo ceramide biosynthesis, improves insulin sensitivity and hepatic steatosis, and protects against atherosclerosis and cardiomyopathy (127, 144).